Transdermal Drug Delivery Systems Market To Show Significant Growth Due To Rise in Prevalence of Chronic Diseases around the World

Transdermal Drug Delivery Systems Market
Transdermal Drug Delivery Systems Market

Overview:

Transdermal drug delivery is a method of administration that allows for the rapid, controlled release of a drug into the bloodstream. These systems can be used to improve oral drug effectiveness, increase patient compliance, and facilitate long-term drug release. However, the system must be designed to provide a sufficient amount of drug. First generation transdermal delivery systems have improved the transport of hydrophilic and lipophilic molecules across skin. The second generation of transdermal delivery systems has introduced new techniques for increasing skin permeability. While, third-generation systems target the stratum corneum, allowing for stronger disruption of the barrier.

Market Dynamics:

Rise in number of people suffering chronic diseases is expected to augment growth of the global Transdermal Drug Delivery Systems Market over the forecast period. The prevalence of chronic disease has increased globally, where traditional drug delivery system such as oral drugs are becoming ineffective, owing to hepatic first-pass metabolism. This in turn is creating demand for these systems of drug delivery. For instance, according to Global RA Network, arthritis, a chronic disease impacted more than 350 people around the world. Moreover, as per the Centers for Disease Control and Prevention, one in four adults suffer arthritis in the U.S.

However, low rate of adoption in emerging markets and high cost of these patches compared other conventional methods of treatment are the factors anticipated to obstruct growth of the global transdermal drug delivery systems for market during the forecast period.

Impact of COVID-19:

The global Transdermal Drug Delivery Systems Market was negatively impacted by the COVID-19 pandemic.

As governments of many countries imposed stringent regulations to control the virus spread, the market witnessed a large gap in the demand and supply chain. As a result, the sales of transdermal drug delivery systems declined significantly. Along with this, the number of patients visits to healthcare centers also reduced during the pandemic, which further increased adoption of prescribed medicines. Thus, these factors negatively impacted the global transdermal drug delivery systems for market during the pandemic.

Key Takeaways:

· The global transdermal drug delivery systems for market to grow with a CAGR of XY% during the forecast period, rise in geriatric population across the globe leading to increased demand for transdermal drug delivery patches. For instance, according to the World Health Organization (WHO), one in six people is likely to be aged 60 years and above by 2030 all over the world and the number is estimated to grow to 2.1 billion by 2050 globally, from 1 billion in 2020.

· North America is anticipated to witness substantial growth in the global Transdermal Drug Delivery Systems Market over the forecast period. This can be attributed to increasing cases of targeted diseases such as central nervous system disorders, chronic pain, and cardiovascular diseases, the rise in number of R&D activities, and growing use of contraceptives in the region.

· Major players functioning in the global transdermal drug delivery systems for market are Transdermal Corporation, Novartis AG, 4P Therapeutics, LLC, Johnson & Johnson, Noven Pharmaceuticals, Inc., Echo Therapeutics, Inc., Mylan Pharmaceuticals, Inc., 3M Company, Boehringer Ingelheim GmbH, Skyepharma, Watson Pharmaceuticals, Inc., Biogel Technology, Inc., and Transdermal Technologies, Inc.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more